National Institute of Arthritis and Musculoskeletal and Skin Diseases 5SB1AR084381-02

Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy

Award to REGENOSINE INC for developing a liposomal adenosine therapy to regenerate cartilage and treat osteoarthritis, including method validation and manufacturing for clinical trials.

Description

Regenosine is developing a liposomal adenosine product for regenerating cartilage in joints affected by osteoarthritis (OA). The project aims to validate analytical methods, establish cGMP manufacturing processes, and produce a sterile batch for clinical trials. The therapy has demonstrated safety and efficacy in animal models, significantly improving pain and slowing OA progression.

View original record